N/A N=20

Changes in Ectopic Fat Following Surgically Induced Weight Loss

Obesity · Type 2 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT00840307 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2017

Primary outcome: Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Texas Southwestern Medical Center
Primary completion: Dec 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Pancreatic and Liver Triglyceride (Fat) Content	6.44; 2.08	—

Summary

This study evaluates how ectopic fat (in the pancreas, heart, liver and skeletal muscle), visceral fat, and subcutaneous fat changes following surgically induced weight loss using gastric banding. The investigators also evaluate whether changes in pancreatic fat content correlate with improvement in beta-cell function.

Eligibility Criteria

Inclusion Criteria

Greater than 18 years old
Fully understanding and willing to undergo study procedures
Available for follow-up
Understand and willing to sign informed consent
Pharmacologic agents with the potential to change ectopic fat content (i.e. pioglitazone) are allowed if the patient has been on a stable dose for at least 3 months and plans to continue the same dose for the duration of the study

Exclusion Criteria

Contraindication to MRI (i.e. metallic implants, severe claustrophobia, weight above 320lb)
Contraindication to phlebotomy (i.e. no accessible veins, hemoglobin <10 mg/dL)
History of pancreatic disease other than diabetes
Regular use of more than 2 alcoholic drinks per day
Pregnancy
Non-English speaking

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00840307). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.